15 Participants Needed

DBS Programming for Essential Tremor

Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Alfonso Fasano
Must be taking: Anti-tremor medication
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores new ways to improve treatment for people with essential tremor, a condition that causes uncontrollable shaking. Researchers are testing a brain stimulation technique called Directional Bilateral Thalamic Patterned Stimulation (VIM-DBS) to determine its safety and effectiveness for those needing surgery and those who have lost benefits from previous treatments. Participants will include individuals with essential tremor who need surgery or those who have already had VIM-DBS but are not experiencing the desired relief. Individuals with essential tremor for at least three years who need surgical intervention or haven't benefited from past brain stimulation might be a good fit. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could lead to better treatment options for essential tremor.

Will I have to stop taking my current medications?

The trial requires that you stay on a stable dose of your anti-tremor medication for at least 4 weeks before screening. So, you should not stop taking your current medications.

What prior data suggests that this device is safe for patients with essential tremor?

Research has shown that deep brain stimulation (DBS) on both sides of the brain for essential tremor is generally well-tolerated. One study found that this treatment significantly reduced tremor symptoms, improving both sides of the body. This suggests the treatment can be effective and safe for many people.

Another study highlighted that using DBS on both sides of the brain has been very effective in reducing tremors, with most patients noticing clear benefits. Although this study didn't focus much on side effects, the positive results suggest the treatment is generally safe.

The current trial is testing new settings and programming for the device, which may result in safety and effectiveness differing slightly from previous studies. However, past research has shown that the basic treatment, DBS, has a strong safety record.12345

Why are researchers excited about this trial?

Directional Bilateral Thalamic Patterned Stimulation is unique because it offers a new way to manage essential tremor by focusing on precise brain stimulation. Unlike traditional deep brain stimulation (DBS), which uses general electrical pulses, this method employs directional leads that can target specific areas in the brain more effectively. Researchers are excited because this precision could lead to better symptom control with fewer side effects, potentially improving the quality of life for patients who haven't found relief with typical DBS approaches.

What evidence suggests that Directional Bilateral Thalamic Patterned Stimulation is effective for essential tremor?

Research has shown that bilateral VIM-DBS, which stimulates both sides of the brain, effectively treats essential tremor. In this trial, participants will receive Directional Bilateral Thalamic Patterned Stimulation, designed to reduce tremors by directing electrical currents more precisely. This precise targeting can lead to better tremor control and improve patients' quality of life. Overall, evidence suggests that this treatment holds promise for effectively managing essential tremor symptoms.12567

Are You a Good Fit for This Trial?

This trial is for patients with tremors, specifically those who have had VIM-DBS treatment but lost its benefits and those needing new VIM-DBS surgery. Up to 20 people will be enrolled, all of whom must have essential tremor and agree to receive a specific device implant.

Inclusion Criteria

Written and signed Informed Consent
I am an Essential Tremor patient needing Deep Brain Stimulation surgery.
Soft signs (categorizing patients as ET-plus) will be allowed and noted in the patient's chart
See 5 more

Exclusion Criteria

Presence of significant psychiatric or cognitive condition likely to compromise the subject's ability to comply with requirements of the study protocol
Any current drug or alcohol abuse, as determined by the investigator
Unwilling or inability to follow the procedures specified by the protocol
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase 1 - Cross-sectional Investigation

Identify the optimal algorithm for patterned stimulation in the VIM region for patients with early or late loss of benefits from previous VIM-DBS treatment.

6 months
Baseline measurement before IPG replacement

Phase 2 - Prospective Clinical Trial

Assessment of safety and efficacy of bilateral VIM-DBS in patients with essential tremor, with programming in four different settings over 8 months.

8 months
Baseline, Month 2, Month 4, Month 6, Month 8

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Directional Bilateral Thalamic Patterned Stimulation
Trial Overview The study tests a DBS programming method using the Chronos software in two phases: first, finding the best stimulation pattern for tremor control; second, evaluating safety and effectiveness of this approach in new patients requiring bilateral VIM deep brain stimulation.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Phase 2Experimental Treatment1 Intervention
Group II: Phase 1Experimental Treatment1 Intervention

Directional Bilateral Thalamic Patterned Stimulation is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as VIM-DBS for:
🇪🇺
Approved in European Union as VIM-DBS for:
🇨🇦
Approved in Canada as VIM-DBS for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Alfonso Fasano

Lead Sponsor

Trials
1
Recruited
20+

Boston Scientific Corporation

Industry Sponsor

Trials
758
Recruited
867,000+
Michael F. Mahoney profile image

Michael F. Mahoney

Boston Scientific Corporation

Chief Executive Officer since 2016

MBA from Wake Forest University, BBA in Finance from the University of Iowa

Kenneth Stein profile image

Kenneth Stein

Boston Scientific Corporation

Chief Medical Officer since 2020

MD from Harvard Medical School, MMSc in Clinical Investigation from Harvard-MIT Division of Health Sciences and Technology

Published Research Related to This Trial

In a study involving 8 patients with essential tremor, short pulse stimulation in the ventral intermediate thalamic nucleus (VIM) effectively reduced stimulation-induced side effects like ataxia and paresthesia while still suppressing tremor severity.
Directional current steering did suppress tremor but did not reduce adverse effects compared to short pulse stimulation, indicating that short pulse stimulation may be a better option for minimizing side effects in deep brain stimulation for tremor.
Thalamic short pulse stimulation diminishes adverse effects in essential tremor patients.Choe, CU., Hidding, U., Schaper, M., et al.[2019]
Unilateral deep brain stimulation (DBS) of the VIM nucleus in the thalamus shows long-term efficacy in reducing essential tremor symptoms, with significant improvements noted in tremor scores at an average follow-up of 40.2 months after surgery.
While the treatment is effective for some patients, it is associated with device-related complications and a risk of loss of efficacy over time, necessitating additional surgical interventions in some cases.
Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor.Koller, WC., Lyons, KE., Wilkinson, SB., et al.[2022]
In a study involving 38 patients with essential tremor, bilateral deep brain stimulation (DBS) of the VIM nucleus resulted in a significant 29.6% additional improvement in total motor tremor scores compared to unilateral DBS, indicating greater efficacy for bilateral treatment.
While bilateral DBS provided enhanced tremor control, it was associated with a slightly higher rate of adverse events, suggesting that while more effective, the risks should be carefully considered.
Benefits and Risks of a Staged-Bilateral VIM Versus Unilateral VIM DBS for Essential Tremor.Prakash, P., Deuschl, G., Ozinga, S., et al.[2022]

Citations

Directional Bilateral Thalamic Patterned Stimulation ...Objectives: The primary objective in Phase 2 is to evaluate the safety and effectiveness of bilateral VIM-DBS in individuals with essential tremor. In Phase 1, ...
Benefits and Risks of a Staged‐Bilateral VIM Versus Unilateral ...Staged‐bilateral VIM DBS was a highly effective treatment for ET with bilateral implantation resulting in greater reduction in total motor tremor scores.
Directional Deep Brain Stimulation of the Thalamic Ventral ...Bilateral thalamic stimulation for the treatment of essential tremor ... Thalamic short pulse stimulation diminishes adverse effects in essential tremor patients.
DBS Programming for Essential TremorResearch suggests that using directional current steering and short pulse stimulation in the thalamus can reduce side effects in essential tremor patients, ...
Directional Bilateral Thalamic Patterned Stimulation ...Benefits: Participation in this study may lead to improved tremor control and quality of life for patients with essential tremor. The study aims to identify an ...
Directional Bilateral Thalamic Patterned Stimulation ...Phase 2 is a prospective clinical trial focusing on the assessment of safety and efficacy of bilateral VIM-DBS in patients with essential tremor ...
Outcomes from stereotactic surgery for essential tremorOverall, bilateral Vim DBS demonstrated more improvement in tremor reduction since both upper extremities were treated (range, 66%–78%). Several studies show ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security